On the afternoon of April 14, a delegation led by Gu Jun, Vice Governor of Liaoning Province, together with relevant officials from the province and the city of Shenyang, visited the Shenzhen-Hong Kong Cell Valley for site inspection and exchanges. The two sides held in-depth discussions on key priorities including high-quality development of the biopharmaceutical industry, clinical translation of emerging biomedical technologies, and the construction of a clinical translation platform for such technologies in Shenyang. They explored pathways for implementation and built consensus for cooperation. Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley Group; Wang Jianxun, Director and Chief Scientist; and Tang Xiaomeng, Deputy General Manager and General Manager of Shenzhen-Hong Kong Cell Valley, led the reception and participated in the subsequent symposium.

The visiting Liaoning delegation included Pan Shuang, Director of the Provincial Department of Commerce; Yang Hui, Deputy Director of the Provincial Department of Science and Technology; Shen Yue, Deputy Director of the Provincial Department of Natural Resources; Zhang Jian, Deputy Director of the Provincial Department of Commerce; Wang Danqun, First-Level Inspector of the Provincial Department of Industry and Information Technology; Wang Mingyu, Chief Economist of the Provincial Development and Reform Commission; and Liu Zhongchen, Director of the Provincial Government’s Office in Guangdong. The Shenyang delegation included Zhang Wenzhe, Vice Mayor; Li Ying, Director of the Municipal Bureau of Commerce; Chu Qi, Deputy Director of the Municipal Bureau of Commerce; Zhang Shaohong, Deputy Director of Shenyang Economic and Technological Development Zone Management Committee; and Wen Miao, Director of the Municipal Government’s Office in Shenzhen.

During the visit, Vice Governor Gu Jun and his delegation inspected the operations of the Shenzhen-Hong Kong Cell Valley, inquiring in detail about the company’s technology platforms, research translation, industrial coordination, and cross-regional cooperation in cell and gene therapy. They examined emerging trends in biomedical technology, clinical research and translation needs, and pathways for building public service platforms, acknowledging the company’s accomplishments and deep cultivation in the field.

At the symposium, Shi Yuanyuan outlined the overall layout, achievements, and future plans of the Cell Valley Group and the Shenyang Cell Valley. He noted that the group has long focused on cell and gene therapy, building a full capability system spanning research services, process development, manufacturing, quality control, and clinical translation support. As the group’s strategic foothold in Northeast China, the Shenyang Cell Valley has become the core carrier for the region’s clinical translation platform. Moving forward, the group will leverage the Shenyang valley to strengthen ties with local authorities, medical institutions, and research units—deepening collaboration on public service platforms for product preparation and quality control, joint research centers and labs with key hospitals, project selection, and clinical research coordination, thereby serving Liaoning’s biopharma development and driving industrial upgrading across the Northeast.

Zhang Wenzhe, Vice Mayor of Shenyang, emphasized that the city places high importance on the life and health industry as a key driver of new productive forces and high-quality growth. It is actively planning to introduce and nurture platform-based projects with leading and catalytic roles. The Shenyang Cell Valley, he said, provides a solid foundation for subsequent clinical translation platform construction, project implementation, and resource integration. Shenyang will maintain close communication with the company, conduct in-depth research on platform needs, hospital cooperation, project uptake mechanisms, resource integration, and support conditions—aligning demand and services to deliver tangible outcomes.

Vice Governor Gu Jun noted that biomedicine and life health are strategic emerging industries that Liaoning prioritizes for development. Integrating technological and industrial innovation is vital for cultivating new productive forces and creating new growth drivers. Liaoning boasts solid industrial foundations, abundant scientific and educational resources, and a strong healthcare system, while Shenyang holds unique advantages in research, clinical application, and industrial capacity—offering ample space for deeper cooperation. He called for strengthened communication and pragmatic planning based on Liaoning’s conditions and policies, focusing on the positioning, implementation pathways, cooperation models, and service functions of the Shenyang Cell Valley project, to actively explore feasible routes for a clinical translation platform, integrate industrial resources efficiently, and support high-quality growth of the province’s biopharma sector.

During the discussions, the parties reached broad consensus on leveraging the current policy window to help key hospitals identify priority disease areas, standardize clinical research filings, co-build research carriers, and reinforce downstream translation support. They agreed on a model of “provincial-level coordination plus key hospital collaboration plus platform-based professional support” to gradually establish a clinical translation and public service system covering major hospitals. With the Shenyang Cell Valley as the core implementation platform, they will refine cooperation measures, assign responsibilities, and ensure orderly, effective delivery of all collaborative initiatives.

The visit not only deepened mutual understanding and built consensus but also laid a solid foundation for the Cell Valley Group to expand its strategic presence in Liaoning and advance the Shenyang clinical translation platform project—crucial steps for promoting high-quality development of Liaoning’s biopharma industry and contributing to the full revitalization of Northeast China.